Abstract: An example thin substrate built-in hard disk drive includes a magnetic disk in a disk shape having a through-hole at the center, a spindle motor inserted into the through-hole of the magnetic disk and co-rotatably supporting the magnetic disk, and a base plate made of an aluminum alloy and supporting the spindle motor. The base plate has a metallographic structure in which a perimeter of a second phase particle having a longest diameter of 10 ?m or more is 3 mm/mm2 or more, and the number of second phase particles having a longest diameter of 500 ?m or more is 0 particles/mm2.

Abstract: A VIPR2 antagonist peptide includes a cyclic peptide comprising an amino acid sequence represented by formula (17): c[X1-Pro-X3-Tyr4-Leu5-Pro6-c(X7-X8-Leu9-Cys10]-X11)-X12-X13 (17), wherein X1 denotes cysteine, Mpa (3-mercaptopropionic acid), or D-cysteine; X3 denotes N-methylglycine, N-methylalanine, 2-azetidine-2-carboxylic acid, proline, hydroxyproline, 3,4-dehydroprolone, pipecolic acid, serine, or lysine; X8 denotes tyrosine, proline, or arginine; X7 and X11 denotes any combination of lysine and aspartic acid, ornithine and glutamic acid, aspartic acid and lysine, glutamic acid and ornithine, lysine and glutamic acid, or glutamic acid and lysine; X12 and X13, each independently denotes leucine, isoleucine, or norleucine; X1 and Cys10 form a disulfide bond between their side chains, and X7 and X11 form an amide bond between their side chains, thereby forming two cyclic structures in a molecule of the peptide of formula (17); and an N-terminal amino group and a C-terminal carboxyl group may be modified.

Abstract: A cyclic peptide or a pharmaceutically acceptable salt of the cyclic peptide includes an amino acid sequence represented by a Formula: c[X1-Pro-X3-c(Cys-X5-Ser-4fF-Asp-Pro-X10-X11)]. X1 denotes a residue of ?-alanine or ?-aminobutyric acid, X3 denotes a residue of leucine, norleucine, cyclohexylglycine, phenylglycine, 2-aminoheptanoic acid, 2-aminooctanoic acid, 2-aminononanonic acid, or 2-aminodecanoic acid, X5 denotes a residue of isoleucine, norleucine, cyclohexylglycine, phenylglycine, 2-aminoheptanoic acid, 2-aminooctanoic acid, 2-aminononanonic acid, or 2-aminodecanoic acid, and X10 denotes a residue of valine, phenylalanine, tryptophane or an N-methyl derivative thereof, X11 denotes a residue of D-cysteine or L-cysteine. X1 and X11 form an amide bond between an amino group and a carboxy group in their main chains, and Cys and X11 form a covalent bond between their side chain sulfhydryl groups via a linker of a methylene group, an ethylene group, a propylene group or a butylene group.

Abstract: The present invention provides a porous carbon material which has been impregnated with a liquid by-product of an amino acid fermentation. The impregnated porous carbon material is effective as a countermeasure against soil injury and plant physiological disorders, and promotes the growth of plants from planting to harvest, and even is useful in continuous cropping.